Back to Journals » Vascular Health and Risk Management » Volume 7

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials

Authors Baumhäkel M, Böhm M

Published 23 June 2011 Volume 2011:7 Pages 391—397

DOI https://doi.org/10.2147/VHRM.S17168

Review by Single-blind

Peer reviewer comments 4


Magnus Baumhäkel, Michael Böhm
Department of Cardiology, University Hospital of Saarland, Homburg Saar, Germany

Abstract: Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk.

Keywords: angiotensin receptor blockers, clinical trials, cardiovascular outcome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]